NCT00478361 - Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder Cancer

Interventions

DRUG

Gemcitabine hydrochloride

Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.

DRUG

Paclitaxel

135 mg/m\^2 IV over 1 hour

DRUG

Doxorubicin hydrochloride

Doxorubicin 40 mg/m\^2 IV over 20 minutes

DRUG

Pegfilgrastim

Subcutaneously injection on day 1.

Trial Locations (2)

65802

Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield, Springfield

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER